OncoMatch/Clinical Trials/NCT06182774
Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma
Is NCT06182774 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Daratumumab and Lenalidomide for multiple myeloma.
Treatment: Daratumumab · Lenalidomide · Dexamethasone · Isatuximab — Currently, daratumumab or isatuximab are given continuously (non-stop), along side lenalidomide, and dexamethasone as part of multiple myeloma treatment. are given continuously (non-stop). Recent observations suggest that stopping daratumumab or isatuximb after about a year and a half of treatment may work just as well as giving them continuously with lenalidomide and dexamethasone. Sometimes, bortezomib is also given. This study is being done to answer the question: is less daratumumab or isatuximab treatment as good as more?
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: daratumumab-lenalidomide-dexamethasone or isatuximab-lenalidomide-dexamethasone (daratumumab, lenalidomide, dexamethasone, isatuximab) — newly diagnosed
Completed 18-20 cycles of daratumumab-lenalidomide-dexamethasone or isatuximab-lenalidomide-dexamethasone.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify